Welcome to Durin Life Sciences.
The leader in early disease detection
Learn more about our Duritect™ tests
Duritect™ tests: Information for patients and caregivers
Duritect™ tests: Information for healthcare providers
The science and research behind our innovative tests
About Durin
Life Sciences
Learn who we are, what we do, and why we do it.
Contact our expert team to explore
collaboration opportunities.
News and events
January 3, 2025
Duritect™ tests to be launched following successful clinical validation
Highly accurate and non-invasive blood-based biomarker (BBM) tests for assessing the risk of Alzheimer's and Parkinson's diseases to be launched shortly following successful CLIA/CAP validation.
August 5, 2024
Durin appoints new Chief Strategy and Commercial Officer
Dennis Hutchison, JD, brings over 20 years of expertise in the diagnostics, lab tools, and pharmaceutical sectors.
August 2, 2024
Durin presents promising early results on its Duritect-AD test at AAIC 2024
Durin attended the Alzheimer's Association International Conference and presented early results on its DuritectTM-AD test which demonstrated one of the highest accuracies among Blood Based Biomarkers (BBMs) in the industry.
Duritect™ tests to be launched following successful clinical validation
January 3, 2025
Highly accurate and non-invasive blood-based biomarker (BBM) tests for assessing the risk of Alzheimer's and Parkinson's diseases to be launched shortly following successful CLIA/CAP validation.
Durin appoints new Chief Strategy and Commercial Officer
August 5, 2024
Dennis Hutchison, JD, brings over 20 years of expertise in the diagnostics, lab tools, and pharmaceutical sectors.
.png)
Durin presents promising early results on its Duritect-AD test at AAIC 2024
August 2, 2024
Durin attended the Alzheimer's Association International Conference and presented early results on its DuritectTM-AD test which demonstrated one of the highest accuracies among Blood Based Biomarkers (BBMs) in the industry.